Flerie writes down Empros Pharma stake, cuts NAV by SEK 2.66 per share

PUBT · 3d ago
Flerie writes down Empros Pharma stake, cuts NAV by SEK 2.66 per share
  • Flerie wrote down the value of its 79% stake in Empros Pharma, citing low prospects of realizing value from development projects.
  • The impairment cuts net asset value by SEK 2.66 per share under the investor’s conservative valuation policy.
  • Empros’ lead asset EMP16 is Phase 3-ready, though required trial scope and GLP-1 competition have hindered financing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Flerie AB published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.